Arcus Biosciences (RCUS) Receivables - Net (2017 - 2018)
Arcus Biosciences (RCUS) recorded quarterly Receivables - Net of $100000.0 in Q4 2018, little changed quarter-over-quarter from $100000.0 in Q3 2018, and up 300.0% on a YoY basis from $25000.0 in Q4 2017.
Arcus Biosciences (RCUS) Receivables - Net (2017 - 2018) Analysis & Trends
Arcus Biosciences' Receivables - Net history runs 2 years deep, the most recent figure standing at $100000.0 for Q4 2018.
- In Q4 2018, Receivables - Net rose 300.0% year-over-year to $100000.0; the TTM figure through Dec 2018 stood at $100000.0 (up 300.0% YoY), while the FY2018 annual figure was $100000.0, up 300.0% from the prior year.
- Receivables - Net was $100000.0 for Q4 2018 at Arcus Biosciences, roughly flat from $100000.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $200000.0 in Q2 2018 to a low of $25000.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Arcus Biosciences | 3.05 Bn | 2.23 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 100,000.00 |
| Dec 31, 2018 | 100,000.00 |
| Sep 30, 2018 | 100,000.00 |
| Sep 30, 2018 | 100,000.00 |
| Jun 30, 2018 | 200,000.00 |
| Jun 30, 2018 | 200,000.00 |
| Mar 31, 2018 | 54,000.00 |
| Mar 31, 2018 | 54,000.00 |
| Dec 31, 2017 | 25,000.00 |
| Dec 31, 2017 | 25,000.00 |